Dostarlimab for the treatment of advanced endometrial cancer-Reference-Cited by-同舟云学术

Dostarlimab for the treatment of advanced endometrial cancer

Published:2022-01-02 Issue:1 Volume:15 Page:1-9
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Redondo Andres¹²³,Gallego Alejandro¹,Mendiola Marta⁴⁵

Affiliation:

1. Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

2. Translational Oncology Research Laboratory, Instituto de Investigación Hospital La Paz (IdiPAZ), Madrid, Spain

3. Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

4. Molecular Pathology and Therapeutic Targets Group, Instituto de Investigación Hospital La Paz (IdiPAZ), Madrid, Spain

5. Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica En Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2022.2044791

Reference41 articles.

1. Cancer Statistics, 2021

2. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

3. Endometrial Cancer

4. Integrated genomic characterization of endometrial carcinoma

5. A clinically applicable molecular-based classification for endometrial cancers

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b);Journal of Medicinal Chemistry;2024-01-05

2. An extension of cancer immunotherapy with dostarlimab, the PD1-PD L1 pathway blocker;Heliyon;2023-12

3. Dostarlimab: Novel paradigm shift in cancer therapy;Tropical Journal of Pharmaceutical Research;2023-10-08

4. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis;Cancers;2023-08-09

5. Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy;Cancers;2023-08-08